Abbvie is a general drug manufacturer company located in Illinois, United States, which is part of the Healthcare sector, and is traded under the ticker ABBV on the NYSE exchange.
Abbvie stock last closed at $170.16, down 1.64% from the previous day, and has increased 1.35% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.03 percentage points. Abbvie stock is currently +10.8% from its 52-week low of $153.58, and -22.18% from its 52-week high of $218.66.
As of Apr 21, 2025, there are 1.77B shares of ABBV outstanding. The market value of ABBV is $300.39B. In the last 24 hours, 7.24M ABBV shares were traded.
How to Buy Abbvie Stock
Not sure how to invest in Abbvie stock? Here's how.
Figure out where to buy Abbvie stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you figure out where to buy Abbvie stock.
Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Deposit funds into your brokerage account: Select your method of payment and add your details.
Evaluate Abbvie stock: The Abbvie ticker symbol is ABBV. Is Abbvie stock a good investment? Should you buy shares of ABBV? How do ABBV's underlying business fundamentals look? Do top analysts think Abbvie is a good buy? Why has ABBV's stock price moved recently? (Hint: Our stock research website can help you decide if ABBV is a good stock to buy).
Execute your ABBV purchase: Decide if you will purchase ABBV shares at the current market price or use a limit order to buy ABBV stock at a given price.
Keep tabs on your investment in ABBV: Create a watchlist to watch your investment in Abbvie stock.
Step 1: Figure out where to buy Abbvie stock
You need a brokerage account in order to access the NYSE market and buy ABBV shares.
A brokerage account allows you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
In our opinion, eToro is the best stock brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
Access to global markets: From Tech to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for a brokerage account
Now that you've selected your brokerage, it's time to fill out some personal details so you are able to invest in ABBV stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Abbvie stock
After you have figured out the best place to buy Abbvie stock, it's important to research their stock before you buy, so you can comprehend the risk as well as the opportunity.
Abbvie Numbers
ABBV Price
$170.16
1w %
-4.99%
1y %
1.35%
5y %
111.75%
P/E
70.9x
P/B
90.34x
P/S
5.34x
PEG
0.82x
Revenue
$56.33B
Earnings
$4.28B
Fore. Rev. Growth
6.92%
Fore. Earn. Growth
86.31%
Market Cap
$300.39B
Next Earnings
Apr 25, 2025
Next Dividend
May 15, 2025
Abbvie Overview
WallStreetZen was created to help part-time investors perform better fundamental analysis quickly.
Total ABBV debt is lower than 5 years ago, relative to shareholder equity.
ABBV's operating cash flow of $18.81B allows it to safely service it's debt of $67.14B.
Failed Health Checks:
ABBV earnings of $5.87B is not enough to cover its interest payments.
ABBV has a relatively high debt to equity ratio of 39.64.
There are more short-term liabilities than short-term assets on the ABBV balance sheet.
ABBV profit margin has gone down from 9% to 7.6% in the past year.
There are more long-term liabilities than short-term assets on the ABBV balance sheet.
Do analysts think it's a good time to buy ABBV stock
Out of 15 sell side analysts who give recommendations on ABBV, the consensus analyst rating on Abbvie is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent ABBV Analyst Upgrades/Downgrades
Geoff Meacham, a bottom 5% analyst from Citigroup maintains ABBV with a strong buy rating and raises their ABBV price target from $205.00 to $215.00, on Feb 3, 2025.
Srikripa Devarakonda, a bottom 9% analyst from Truist Securities maintains ABBV with a strong buy rating and raises their ABBV price target from $211.00 to $217.00, on Feb 3, 2025.
Navin Jacob, a top 26% analyst from UBS maintains ABBV with a hold rating and raises their ABBV price target from $181.00 to $190.00, on Feb 3, 2025.
Gary Nachman, a bottom 16% analyst from Raymond James reiterates ABBV with a buy rating and raises their ABBV price target from $218.00 to $220.00, on Feb 3, 2025.
Evan David Seigerman, a top 23% analyst from BMO Capital maintains ABBV with a buy rating and raises their ABBV price target from $208.00 to $215.00, on Feb 3, 2025.
You can dive deeper into what analysts are projecting on the Abbvie stock forecast page.
ABBV Momentum
SMA10
176.2
SMA20
189.57
SMA50
198.99
SMA100
188.29
SMA200
188.01
MACD
-8.75
MACD Signal
-6.61
MACD Histogram
-2.14
RSI
28.4
Stochastic %K
15.12
Stochastic %D
19.63
StochRSI %K
20.09
StochRSI %D
22.19
ABBV Earnings
Last year, ABBV earnings were $4.28B. During the past 5 year, ABBV's earnings have gone up by -14.65% per year. This was slower than the Drug Manufacturers - General industry average of 0.89%.
Last year, ABBV revenue was $56.33B. In the last 5 year, ABBV's revenue has grown by 11.11% per year. This was faster than the Drug Manufacturers - General industry average of 9.15%.
Over the past year, insiders at ABBV have sold more shares than they have bought.
Jeffrey Ryan Stewart, EVP CHIEF COMMERCIAL OFFICER of ABBV, was the latest ABBV insider to buy. They bought $2,030,814.00 worth of ABBV stock on Mar 31, 2025.
Abbvie pays a dividend of 2.79%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.51%. If you owned $1,000 of ABBV stock, you would have been paid $27.86 last year.
Abbvie dividend payments have consistently grown over the past decade and have remained stable.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Execute your ABBV purchase
You have two main order types:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are mostly fine.
Limit order: A limit order is an order to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a particular price limit, place a limit order.
Click the Open Trade button and eToro will place the order.
If you require more info about buying stocks on eToro, click the how to video below:
As of Apr 21, 2025, it costs $170.16 to buy one share of Abbvie stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.588 shares of ABBV.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.